TMDX

TransMedics Group, Inc. [TMDX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TMDX Stock Summary

Top 10 Correlated ETFs

TMDX

Top 10 Correlated Stocks

TMDX

In the News

TMDX Financial details

Company Rating
-
Market Cap
3B
Income
-25.03M
Revenue
241.62M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
584
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-78.11
Forward P/E
-
PEG
21
P/S
14.58
P/B
22.1
P/C
-
P/FCF
-118.69
Quick Ratio
9.93
Current Ratio
10.93
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
-37.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-20.07%
Revenue last 5Y
59.23%
Revenue Q/Q
22.19%
EPS Q/Q
-115.38%
-
-
-
-
SMA20
-12.74%
SMA50
-16.35%
SMA100
29.09%
Inst Own
-
Inst Trans
-
ROA
-5%
ROE
-22%
ROC
-0.06%
Gross Margin
66%
Oper. Margin
-20%
Profit Margin
-19%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
36.42-99.63
52W High
+15.72%
52W Low
+218.24%
RSI
49.97
Rel Volume
1.13
Avg Volume
696.83K
Volume
785.55K
Perf Week
7.13%
Perf Month
-3.7%
Perf Quarter
65.92%
Perf Half Y
70.79%
-
-
-
-
Beta
2.001
-
-
Volatility
4.74%, 8.01%
Prev Close
-2.07%
Price
114.565
Change
5.84%

Something similar

Top by Market Cap
FXAIX
LLY.DE
APC.DE
FB2A.DE
BRK-B
Top Correlated ETFs
BITO
305720.KS
305540.KS
364980.KS
BCDF
Top Correlated Stocks
NTBR.L
NVTS
6954.T
CDXS
0N7N.L
Similar Market Cap
002452.SZ
SDLAX
EELT.ME
HSBK.IL
LSWWX

Company Profile

Healthcare Medical - Devices
  • Volume Average 696.83K
  • Market Capitalization 3B
  • Employee 584
  • CEO Dr. Waleed H. Hassanein M.D.
  • Headquarters Andover,MA,US
  • IPO Date 2019-05-02
  • Website https://www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.